Corbus公布CRB-913减肥1b期阳性数据：安全性优于Novo/Sanofi旧药但疗效仅追平口服Wegovy，股价盘前冲高25%后大幅回落

Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi | Fierce Biotech
Biotech
Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi
By
Nick Paul Taylor
Sep 14, 2026 10:07am
Corbus Pharmaceuticals
obesity drugs
weight loss
cannabinoids
Corbus Pharmaceuticals’ phase 1b obesity trial has
generated
evidence its CB1 inverse agonist may be less prone to the neuropsychiatric side effects that haunted Novo Nordisk and Sanofi.
Sanofi won European approval for a CB1 receptor blocker weight loss drug, Acomplia, in 2006, only for evidence that the medicine doubles the risk of psychiatric disorders to force the product off the market three years later. Novo resurrected interest in the mechanism in 2023 by
inking
a deal to buy Inversago Pharma for up to $1.1 billion. But the following year the Danish drugmaker
reported
neuropsychiatric side effects from Inversago's drug monlunabant in a phase 2 trial.
With Novo
axing
monlunabant, Corbus has a chance to establish CRB-913 as the frontrunner in the CB1 race. The phase 1b data contain positive signs mixed with scope to question whether Corbus has seized the opportunity, leaving the biotech’s stock up 4% at $8.48 in early trading.
At a Jefferies event in June, Corbus CEO Yuval Cohen, Ph.D., said “pretty much the only question is are we going to look safer than monlunabant in terms of the neuropsych [adverse events].” The study succeeded by Cohen’s yardstick, with Corbus reporting lower rates of depression, anxiety, irritability and insomnia than Novo
saw
in its phase 2a trial.
Rates of the adverse events on the highest dose of CRB-913 ranged from 0% to 9.7%. Corbus compared its data to placebo and GLP-1 receptor agonists, showing that small numbers of people report psychiatric events while taking drugs such as Novo’s Wegovy and Eli Lilly’s Zepbound.
Corbus reported placebo-adjusted weight loss of up to 5% at Week 12, in line with the 5.8% that Novo saw at Week 16 of its phase 2a trial and well ahead of the efficacy of Acomplia. The CRB-913 result is in the same ballpark as the phase 3 data that Novo
published
on oral Wegovy. There was no evidence that weight loss was plateauing at Week 12, pointing to the potential for deeper declines in longer trials.
Little evidence suggests that CRB-913 can improve significantly on the efficacy of oral Wegovy, but Corbus’ candidate could be a more tolerable option. CRB-913’s rates of vomiting, nausea and constipation compare favorably to data for Wegovy pill and Lilly’s Foundayo, although numerically more people had diarrhea on CRB-913 than on the existing oral obesity drugs.
Corbus Pharmaceuticals
obesity drugs
weight loss
cannabinoids
Biotech
Clinical Data